Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand; Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan 646000, China.
Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan 646000, China.
Biomed Pharmacother. 2024 Jul;176:116922. doi: 10.1016/j.biopha.2024.116922. Epub 2024 Jun 12.
The intricate crosstalk between long noncoding RNAs (lncRNAs) and epigenetic modifications such as chromatin/histone methylation and acetylation offer new perspectives on the pathogenesis and treatment of kidney diseases. lncRNAs, a class of transcripts longer than 200 nucleotides with no protein-coding potential, are now recognized as key regulatory molecules influencing gene expression through diverse mechanisms. They modulate the epigenetic modifications by recruiting or blocking enzymes responsible for adding or removing methyl or acetyl groups, such as DNA, N6-methyladenosine (m6A) and histone methylation and acetylation, subsequently altering chromatin structure and accessibility. In kidney diseases such as acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy (DN), glomerulonephritis (GN), and renal cell carcinoma (RCC), aberrant patterns of DNA/RNA/histone methylation and acetylation have been associated with disease onset and progression, revealing a complex interplay with lncRNA dynamics. Recent studies have highlighted how lncRNAs can impact renal pathology by affecting the expression and function of key genes involved in cell cycle control, fibrosis, and inflammatory responses. This review will separately address the roles of lncRNAs and epigenetic modifications in renal diseases, with a particular emphasis on elucidating the bidirectional regulatory effects and underlying mechanisms of lncRNAs in conjunction with DNA/RNA/histone methylation and acetylation, in addition to the potential exacerbating or renoprotective effects in renal pathologies. Understanding the reciprocal relationships between lncRNAs and epigenetic modifications will not only shed light on the molecular underpinnings of renal pathologies but also present new avenues for therapeutic interventions and biomarker development, advancing precision medicine in nephrology.
长链非编码 RNA(lncRNA)与表观遗传修饰(如染色质/组蛋白甲基化和乙酰化)之间的复杂串扰为肾脏疾病的发病机制和治疗提供了新的视角。lncRNA 是一类转录本长度超过 200 个核苷酸且没有蛋白编码潜能的 RNA 分子,它们被认为是通过多种机制影响基因表达的关键调节分子。它们通过招募或阻断负责添加或去除甲基或乙酰基的酶来调节表观遗传修饰,例如 DNA、N6-甲基腺苷(m6A)和组蛋白甲基化和乙酰化,从而改变染色质结构和可及性。在急性肾损伤(AKI)、慢性肾脏病(CKD)、糖尿病肾病(DN)、肾小球肾炎(GN)和肾细胞癌(RCC)等肾脏疾病中,异常的 DNA/RNA/组蛋白甲基化和乙酰化模式与疾病的发生和进展相关,揭示了与 lncRNA 动态的复杂相互作用。最近的研究强调了 lncRNA 如何通过影响参与细胞周期控制、纤维化和炎症反应的关键基因的表达和功能来影响肾脏病理。本文将分别探讨 lncRNA 和表观遗传修饰在肾脏疾病中的作用,特别强调阐明 lncRNA 与 DNA/RNA/组蛋白甲基化和乙酰化之间的双向调节作用及其潜在机制,以及在肾脏病理中的潜在恶化或肾保护作用。了解 lncRNA 和表观遗传修饰之间的相互关系不仅可以揭示肾脏病理的分子基础,还可以为治疗干预和生物标志物开发提供新途径,推进肾脏病学的精准医学。